Cytokine Three-Step Method: 1000-Fold CIK Cell Expansion in 14 Days, with ≥20% CD3⁺CD56⁺ and >80% Killing Rate

One-Sentence Conclusion

Using the UA-IFN-γ/IL-2/IL-1α three-step sequential culture, PBMCs can be expanded 1000-fold in 14 days, yielding highly active CIK cells with ≥20% CD3⁺CD56⁺ and >80% in vitro cytotoxicity, fully meeting clinical reinfusion standards.

What are CIK Cells? Why are They Called the "Elite Anti-Tumor Forces"?

• Dual-Positive Effect: The CD3⁺CD56⁺ phenotype combines the antigen-specific recognition of T cells with the non-MHC-restricted killing ability of NK cells.
  

• Wide Safety Window: They primarily target tumor cells, sparing normal tissues, resulting in fewer side effects compared to CAR-T.
  
  

Three-Step Activation Method

Results: After 14 days, total cell count expands 1000x, viability >80%, CD3⁺CD56⁺ ≥20% (by flow cytometry), and LDH cytotoxicity >80% (at E:T ratio=20:1).

3 Core Advantages of UA Cytokines

• High Specific Activity: e.g., IFN-γ ≥5×10⁷ U/mg, ensuring successful D0 priming.
  
  

• Low Endotoxin: <0.1 EU/μg, suitable for direct use in clinical-grade CIK preparation.
  
  

• Low Batch-to-Batch Variation: GMP-grade purification, CV <5%, ensuring high experimental reproducibility.
  
  

5 Major Application Scenarios

1. Autologous CIK reinfusion for hematological malignancies
   
   

2. Adjuvant immunotherapy post-solid tumor surgery
   
   

3. Tumor antigen-specific cytotoxicity evaluation
   
   

4. High-throughput screening combined with immune checkpoint inhibitors
   
   

5. Process development for GMP-grade cell products
   
   

UA Bio Ready-to-Use List (Cat. No. + Size)